Clinical Trials Browser

Terminated × apatinib × Clear all

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04119453 2024-06-24

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Phase 2 Terminated

Carcinoma, Adenoid Cystic

NCT04073615 2024-05-02

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Phase 1 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT03711279 2024-02-29

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Phase 2 Terminated

99 enrolled 10 charts

Sarcoma

NCT03251417 2023-02-01

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Terminated

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03707028 2022-04-11

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Phase 1/2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT02874651 2022-01-11

ADVANCE

Phase 2 Terminated

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT03256721 2021-02-08

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03407976 2020-07-15

APPEASE

Phase 1 Terminated

Adenocarcinoma, Carcinoma, Transitional Cell

NCT03349827 2020-03-24

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Phase NA Terminated

Gastrointestinal

Peritoneal Metastases From Gastric Cancer